{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:16:52Z","timestamp":1783603012632,"version":"3.55.0"},"reference-count":57,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of heterogenous hematologic malignancies characterized by the proliferation of blood cells and consist of myelofibrosis, polycythemia vera, and essential thrombocythemia. The NCCN Guidelines for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim of providing recommendations for the comprehensive care of adults with these diseases. The panel of experts convenes at least once a year to discuss requested changes to the Guidelines and to evaluate emerging data. These Guideline Insights focus on some of the recent updates for myelofibrosis.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0034","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:35Z","timestamp":1783600895000},"source":"Crossref","is-referenced-by-count":0,"title":["NCCN Guidelines\u00ae Insights: Myeloproliferative Neoplasms, Version 2.2026"],"prefix":"10.6004","volume":"24","author":[{"given":"Aaron T.","family":"Gerds","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Abdelmessieh","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Chernak","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel R.","family":"Espinoza-Gutarra","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Fein Revell","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Green","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Gundabolu","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona H.","family":"Jamieson","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irum","family":"Khan","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"McMahon","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R.","family":"Mohan","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan V.","family":"Nadiminti","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Oh","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand A.","family":"Patel","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Rein","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Salit","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sehl","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Wall","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Bergman","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hochstetler","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Blood","first-page":"Abstract 5576","article-title":"Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States","volume":"146","author":"Gerds A","year":"2025","unstructured":"Gerds A, Rein L, Engel-Nitz N,  Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States. Blood 2025;146:Abstract 5576."},{"key":"B2","series-title":"Leuk Lymphoma","first-page":"694","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek S","year":"2022","unstructured":"Verstovsek S, Yu J, Scherber RM,  Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma 2022;63:694\u2013702."},{"key":"B3","series-title":"Am J Hematol","first-page":"50","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi A","year":"2016","unstructured":"Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol 2016;91:50\u201358."},{"key":"B4","series-title":"J Natl Compr Canc Netw","first-page":"424","article-title":"Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms","volume":"13","author":"Stein BL","year":"2015","unstructured":"Stein BL, Gotlib J, Arcasoy M,  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw 2015;13:424\u2013434."},{"key":"B5","series-title":"Am J Hematol","first-page":"741","article-title":"Comparative clinical and molecular landscape of primary and secondary myelofibrosis: superior performance of MIPSS70+ v2.0 over MYSEC-PM","volume":"99","author":"Guerra M","year":"2024","unstructured":"Guerra M, Pasquer H, Daltro de Oliveira R,  Comparative clinical and molecular landscape of primary and secondary myelofibrosis: superior performance of MIPSS70+ v2.0 over MYSEC-PM. Am J Hematol 2024;99:741\u2013744."},{"key":"B6","series-title":"Blood Cancer J","first-page":"110","article-title":"Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model","volume":"13","author":"Shide K","year":"2023","unstructured":"Shide K, Takenaka K, Kitanaka A,  Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model. Blood Cancer J 2023;13:110."},{"key":"B7","series-title":"Leukemia","first-page":"2726","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti F","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B,  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017;31:2726\u20132731."},{"key":"B8","series-title":"Semin Hematol","first-page":"248","article-title":"Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study","volume":"55","author":"Palandri F","year":"2018","unstructured":"Palandri F, Palumbo GA, Iurlo A,  Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. Semin Hematol 2018;55:248\u2013255."},{"key":"B9","series-title":"Lancet","first-page":"269","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek S","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM,  Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401:269\u2013280."},{"key":"B10","series-title":"Lancet Haematol","first-page":"e735","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds AT","year":"2023","unstructured":"Gerds AT, Verstovsek S, Vannucchi AM,  Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 2023;10:e735\u2013746."},{"key":"B11","series-title":"J Clin Oncol","first-page":"3844","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa RA","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV,  SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 2017;35:3844\u20133850."},{"key":"B12","series-title":"Leukemia","first-page":"2261","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa R","year":"2022","unstructured":"Mesa R, Harrison C, Oh ST,  Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 2022;36:2261\u20132268."},{"key":"B13","series-title":"Lancet Haematol","first-page":"e73","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison CN","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U,  Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 2018;5:e73\u201381."},{"key":"B14","series-title":"Value Health","first-page":"607","article-title":"Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies","volume":"27","author":"Hudgens S","year":"2024","unstructured":"Hudgens S, Verstovsek S, Floden L,  Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies. Value Health 2024;27:607\u2013613."},{"key":"B15","series-title":"Lancet Haematol","first-page":"e225","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa RA","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A,  Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 2017;4:e225\u2013236."},{"key":"B16","series-title":"JAMA Oncol","first-page":"652","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas J","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M,  Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 2018;4:652\u2013659."},{"key":"B17","series-title":"Eur J Haematol","first-page":"238","article-title":"Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival","volume":"114","author":"Ajufo H","year":"2025","unstructured":"Ajufo H, Bewersdorf JP, Harrison C,  Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival. Eur J Haematol 2025;114:238\u2013247."},{"key":"B18","series-title":"Ann Hematol","first-page":"1233","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"Martinez-Trillos A","year":"2010","unstructured":"Martinez-Trillos A, Gaya A, Maffioli M,  Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233\u20131237."},{"key":"B19","series-title":"Cancer","first-page":"2680","article-title":"The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis","volume":"123","author":"Silver RT","year":"2017","unstructured":"Silver RT, Barel AC, Lascu E,  The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis. Cancer 2017;123:2680\u20132687."},{"key":"B20","series-title":"Br J Haematol","first-page":"29","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial","volume":"170","author":"Mead AJ","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S,  Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol 2015;170:29\u201339."},{"key":"B21","series-title":"Haematologica","first-page":"1065","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali HK","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, Le Coutre P,  Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 2016;101:1065\u20131073."},{"key":"B22","series-title":"Adv Hematol","first-page":"848473","article-title":"Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib","volume":"2015","author":"Davis KL","year":"2015","unstructured":"Davis KL, Cote I, Kaye JA,  Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol 2015;2015:848473."},{"key":"B23","series-title":"Lancet Haematol","first-page":"e196","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger H","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P,  Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 2020;7:e196\u2013208."},{"key":"B24","series-title":"Lancet Haematol","first-page":"e862","article-title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","volume":"12","author":"Mesa R","year":"2025","unstructured":"Mesa R, Gill H, Zhang L,  Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol 2025;12:e862\u2013875."},{"key":"B25","series-title":"Br J Haematol","first-page":"244","article-title":"Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis","volume":"195","author":"Pardanani A","year":"2021","unstructured":"Pardanani A, Tefferi A, Masszi T,  Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol 2021;195:244\u2013248."},{"key":"B26","series-title":"N Engl J Med","first-page":"799","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J,  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799\u2013807."},{"key":"B27","series-title":"Haematologica","first-page":"479","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek S","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J,  Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 2015;100:479\u2013488."},{"key":"B28","series-title":"J Hematol Oncol","first-page":"55","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek S","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J,  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 2017;10:55."},{"key":"B29","series-title":"N Engl J Med","first-page":"787","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison C","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK,  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787\u2013798."},{"key":"B30","series-title":"Blood","first-page":"4047","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes F","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ,  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047\u20134053."},{"key":"B31","series-title":"Blood Adv","first-page":"1965","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin K","year":"2020","unstructured":"Gowin K, Ballen K, Ahn KW,  Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv 2020;4:1965\u20131973."},{"key":"B32","series-title":"N Engl J Med","first-page":"150","article-title":"Clearance of driver mutations after transplantation for myelofibrosis","volume":"392","author":"Gagelmann N","year":"2025","unstructured":"Gagelmann N, Quarder M, Badbaran A,  Clearance of driver mutations after transplantation for myelofibrosis. N Engl J Med 2025;392:150\u2013160."},{"key":"B33","series-title":"Leukemia","first-page":"2862","article-title":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","volume":"39","author":"Salit RB","year":"2025","unstructured":"Salit RB, Hexner EO, Gagelmann N,  Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus. Leukemia 2025;39:2862\u20132865."},{"key":"B34","series-title":"Blood","first-page":"2895","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes F","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A,  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895\u20132901."},{"key":"B35","series-title":"Mayo Clin Proc","first-page":"25","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi A","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T,  One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012;87:25\u201333."},{"key":"B36","series-title":"Blood","first-page":"1738","article-title":"How I treat anemia in myelofibrosis","volume":"145","author":"Jain AG","year":"2025","unstructured":"Jain AG, Gerds AT. How I treat anemia in myelofibrosis. Blood 2025;145:1738\u20131746."},{"key":"B37","series-title":"Blood","first-page":"1813","article-title":"Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis","volume":"144","author":"Tefferi A","year":"2024","unstructured":"Tefferi A, Barosi G, Passamonti F,  Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood 2024;144:1813\u20131820."},{"key":"B38","series-title":"Leuk Lymphoma","first-page":"965","article-title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","volume":"65","author":"Gupta V","year":"2024","unstructured":"Gupta V, Oh S, Devos T,  Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 2024;65:965\u2013977."},{"key":"B39","series-title":"Adv Ther","first-page":"3722","article-title":"Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-2","volume":"41","author":"Harrison CN","year":"2024","unstructured":"Harrison CN, Vannucchi AM, Recher C,  Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-2. Adv Ther 2024;41:3722\u20133735."},{"key":"B40","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"199","article-title":"Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib","volume":"25","author":"Harrison CN","year":"2025","unstructured":"Harrison CN, Mesa R, Talpaz M,  Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib. Clin Lymphoma Myeloma Leuk 2025;25:199\u2013211."},{"key":"B41","series-title":"Blood Adv","first-page":"5835","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh ST","year":"2023","unstructured":"Oh ST, Mesa RA, Harrison CN,  Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7:5835\u20135842."},{"key":"B42","series-title":"Exp Hematol Oncol","first-page":"26","article-title":"The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis","volume":"4","author":"McMullin MF","year":"2015","unstructured":"McMullin MF, Harrison CN, Niederwieser D,  The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol 2015;4:26."},{"key":"B43","series-title":"Br J Haematol","first-page":"701","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Crisa E","year":"2018","unstructured":"Crisa E, Cilloni D, Elli EM,  The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol 2018;182:701\u2013704."},{"key":"B44","series-title":"Eur J Haematol","first-page":"154","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang J","year":"2009","unstructured":"Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009;83:154\u2013155."},{"key":"B45","series-title":"Ann Hematol","first-page":"1791","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes F","year":"2015","unstructured":"Cervantes F, Isola IM, Alvarez-Larran A,  Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 2015;94:1791\u20131796."},{"key":"B46","article-title":"Danazol [Internet]","author":"Ashfaq S","unstructured":"Ashfaq S, Pellegrini MV, Can AS,  Danazol [Internet]. StatPearls Publishing. Accessed May 20, 2026. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564344\/"},{"key":"B47","series-title":"Br J Haematol","first-page":"399","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes F","year":"2004","unstructured":"Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC,  Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127:399\u2013403."},{"key":"B48","series-title":"Br J Haematol","first-page":"184","article-title":"Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes F","year":"2006","unstructured":"Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC,  Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006;134:184\u2013186."},{"key":"B49","series-title":"Acta Haematol","first-page":"156","article-title":"Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis","volume":"117","author":"Tsiara SN","year":"2007","unstructured":"Tsiara SN, Chaidos A, Bourantas LK,  Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol 2007;117:156\u2013161."},{"key":"B50","series-title":"Blood Adv","first-page":"4511","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","volume":"8","author":"Gerds AT","year":"2024","unstructured":"Gerds AT, Harrison CN, Kiladjian JJ,  Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv 2024;8:4511\u20134522."},{"key":"B51","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"Abstract MPN\u2013346","article-title":"Independence: enrolling phase III trial to study the efficacy and safety of luspatercept versus placebo in patients with myelofibrosis on JAK2 inhibitor (JAK2i) therapy requiring red blood cell transfusions (RBCTs)","volume":"23","author":"Kiladjian JJ","year":"2023","unstructured":"Kiladjian JJ, Harrison C, Mesa RA,  Independence: enrolling phase III trial to study the efficacy and safety of luspatercept versus placebo in patients with myelofibrosis on JAK2 inhibitor (JAK2i) therapy requiring red blood cell transfusions (RBCTs). Clin Lymphoma Myeloma Leuk 2023;23:Abstract MPN\u2013346."},{"key":"B52","series-title":"Blood","first-page":"1158","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi A","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S,  Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158\u20131164."},{"key":"B53","series-title":"J Clin Oncol","first-page":"4760","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quintas-Cardama A","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian HM, Manshouri T,  Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760\u20134766."},{"key":"B54","series-title":"Blood","first-page":"4436","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa RA","year":"2010","unstructured":"Mesa RA, Yao X, Cripe LD,  Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436\u20134438."},{"key":"B55","series-title":"Leuk Res","first-page":"1","article-title":"Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis","volume":"48","author":"Chihara D","year":"2016","unstructured":"Chihara D, Masarova L, Newberry KJ,  Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res 2016;48:1\u20135."},{"key":"B56","series-title":"Leuk Res","first-page":"1927","article-title":"Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases","volume":"32","author":"Santana-Davila R","year":"2008","unstructured":"Santana-Davila R, Tefferi A, Holtan SG,  Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. Leuk Res 2008;32:1927\u20131930."},{"key":"B57","series-title":"Blood","first-page":"899","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour E","year":"2011","unstructured":"Jabbour E, Thomas D, Kantarjian H,  Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118:899\u2013902."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e260034.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e260034.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e260034.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:36Z","timestamp":1783600896000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e260034.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0034","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}